Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $16.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-03-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-12-31 was $3.80M, a 90.00% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-09-30 was $3.30M, a 50.00% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-06-30 was $3.10M, a 40.91% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $6.30M, a 70.27% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $16.50M, a 63.37% increase from fiscal 2021.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $10.10M, a 4950.00% increase from fiscal 2020.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $200.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2022-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $7.10M derived: sum of 2 quarters · filed 2023-03-03 | $10.20M derived: sum of 3 quarters · filed 2023-03-03 | $16.50M 10-K · filed 2023-03-03 |
| 2022-09-30 | $3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.40M derived: sum of 2 quarters · filed 2022-11-03 | $12.70M 10-Q · filed 2022-11-03 | $14.70M derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.40M 10-Q · filed 2022-08-04 | $11.40M derived: sum of 3 quarters · filed 2023-03-03 | $13.60M derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-03-31 | $6.30M 10-Q · filed 2022-05-05 | $8.30M derived: sum of 2 quarters · filed 2023-03-03 | $10.50M derived: sum of 3 quarters · filed 2023-03-03 | $12.70M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $4.20M derived: sum of 2 quarters · filed 2023-03-03 | $6.40M derived: sum of 3 quarters · filed 2023-03-03 | $10.10M 10-K · filed 2023-03-03 |
| 2021-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.40M derived: sum of 2 quarters · filed 2021-11-04 | $8.10M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.90M 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $3.70M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $200.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |